Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients.
About FDA Designations
The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application.
The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by providing seven years of market exclusivity, tax credits for clinical trials, and waiver of certain FDA fees.
About Wilson Disease (WD) and IN013
Wilson Disease (WD), or Hepatolenticular Degeneration (HLD), is a rare and life-threatening autosomal recessive disorder caused by mutations in the ATP7B gene, leading to toxic copper accumulation in the liver, brain, kidneys, and other organs. Symptoms include hepatic and neurological damage, ocular abnormalities, kidney injury, hemolysis, and skeletal complications. Current treatments offer limited efficacy and carry risks such as hepatorenal toxicity or exacerbated neurological symptoms.
IN013, developed using Innorna’s mRNA-LNP platform, targets the root cause of WD by restoring functional ATP7B protein levels. By reducing systemic copper buildup, IN013 aims to alleviate multi-organ damage and deliver disease-modifying benefits.
About Innorna
Founded in 2019, Innorna is committed to developing state-of-the-art LNP delivery systems and RNA therapies to address unmet medical needs. Its proprietary Diversity-Oriented Lipid Library—with over 5,000 ionizable lipids—enables breakthroughs in mRNA vaccines, gene editing, and cell therapies.
With its innovative mRNA-LNP platform, Innorna has built a robust pipeline targeting infectious diseases, rare genetic disorders, and cancer immunotherapy. Beyond its internal R&D efforts, the company collaborates with global-leading biotechnology partners to expand the reach of its transformative technology.
Innorna’s achievements have earned recognition as one of MIT Technology Review’s Global Top 50 Smartest Companies and Fortune China’s Most Socially Influential Startups. Guided by INNOVATION, INTEGRITY, EFFICIENCY, and OPENNESS, Innorna drives its mission to revolutionize mRNA applications and make a global impact.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250427120055/en/
Contacts
Innorna Co. Ltd.
info@innorna.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
DEWA PJSC added to the MSCI Emerging Markets Index14.5.2025 18:17:00 EEST | Press release
MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), is in the MSCI Emerging Markets Index, effective as of the market close on 30 May 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514839494/en/ HE Saeed Mohammed Al Tayer, Vice Chairman and MD & CEO of DEWA (Photo: AETOSWire) “DEWA is proud to be the largest listed company on the Dubai Financial Market, with a market capitalization exceeding AED 130 billion. Our inclusion in the MSCI Emerging Markets Index marks a pivotal milestone in DEWA’s journey as a publicly listed company and reinforces our growing relevance on the global investment stage. DEWA was among largest additi
IEEE Provides Strategic Expertise as Indonesia Adopts First Age-Appropriate Design Regulation in Asia14.5.2025 18:00:00 EEST | Press release
The IEEE Standards Association (IEEE SA), the global, consensus-building standards development organization of IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, announces the culmination of its collaboration with policymakers on the recently passed Indonesian Government Regulation, Governance of Electronic Systems in Child Protection. Through insights and expertise grounded in the IEEE’s initiatives and standards on children’s data governance and age-appropriate design, IEEE SA advanced frameworks for the age-appropriate design of internet platforms and systems in Indonesia’s regulatory process. This regulation is the first of its kind in Asia and the Global South, establishing enforceable requirements for digital platforms to protect children’s privacy, safety, and well-being, as a robust, holistic approach against children’s online addiction. Indonesia’s adoption of this landmark regulation represents a significant step forw
Creative Visionary Nicola Formichetti Named Global Creative Director, M·A·C Cosmetics14.5.2025 17:10:00 EEST | Press release
The Estée Lauder Companies (NYSE:EL) and M·A·C Cosmetics announced today the appointment of Nicola Formichetti as Global Creative Director, effective May 19, 2025. A celebrated creative director, designer, and cultural icon, Formichetti brings his visionary artistry, genre-defying creativity and consumer-first mindset to the helm of M·A·C’s global creative strategy. He will report directly to Aïda Moudachirou-Rébois, M·A·C’s Senior Vice President and Global General Manager. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514389264/en/ Photograph by Matthew Brookes Formichetti’s appointment marks a pivotal moment for M·A·C as the brand continues to shape the future of beauty through boundary-pushing innovation and cultural relevance. His dynamic approach to creativity, rooted at the intersection of fashion, music, culture, and technology, will spark new levels of desirability for M·A·C, driving its product innovation, creat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom